Novartis

[video]Did Novartis Overpay for AveXis?
[video]Did Novartis Overpay for AveXis?
Motley Fool
Novartis
AveXis
gene therapy
M&A
Flag link:
Q1 kicks off with J&J, Novartis, Glaxo results
Q1 kicks off with J&J, Novartis, Glaxo results
Biopharma Dive
earnings
JNJ
Novartis
GSK
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
AveXis
Abeona Therapeutics
Spectrum Pharmaceuticals
Novartis
M&A
poziotinib
EB-101
Flag link:
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Forbes
Novartis
Pharma CEOs
FDA
drug pricing
Vasant Narasimham
Flag link:
Novartis offloads failed cancer drug to Oncology Venture
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Novartis
Oncology Venture
dovitinib
kidney cancer
cancer
Flag link:
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Fierce Pharma
physician payments
Novartis
Pfizer
Bayer
Bristol-Myers Squibb
cancer
Flag link:
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Forbes
Novartis
Vas Narasimhan
M&A
gene therapy
AveXis
Flag link:
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Marketwatch
Novartis
AveXis
Biogen
SMA
M&A
AVXS-1-1
Spinraza
Flag link:
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Novartis
M&A
AveXis
gene therapy
AVXS-101
SMA
spinal muscular atrophy
Flag link:
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Fierce Pharma
Novartis
China
Greece
kickbacks
bribery
Flag link:
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Conatus Pharmaceuticals
clinical trials
Novartis
emricasan
liver disease
hepatitis C
Flag link:
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Investors Business Daily
Novartis
Amgen
Enbrel
biosimilars
Flag link:
Novartis sues Regeneron over manufacturing methods
Novartis sues Regeneron over manufacturing methods
Biopharma Dive
Novartis
Regeneron
drug manufacturing
Zaltrap
Eylea
Flag link:
GSK buys out Novartis in $13 billion consumer healthcare shake-up
GSK buys out Novartis in $13 billion consumer healthcare shake-up
Yahoo/Reuters
GSK
Novartis
consumer healthcare
M&A
Flag link:
Pharma's social media strategies are growing up—and working better, too, report finds
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Flag link:
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
CP Wire
Novartis
siponimod
clinical trials
MS
multiple sclerosis
SPMS
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Novartis, Harvard team up to develop immunotherapy drug-delivery systems
Novartis, Harvard team up to develop immunotherapy drug-delivery systems
Drug Delivery Business News
Novartis
Harvard
immunotherapy
drug delivery
R&D
immuno-oncology
Flag link:
Novartis sales rep said that reps were “essentially buying scripts” as seven-year old case moves to trial
Novartis sales rep said that reps were “essentially buying scripts” as seven-year old case moves to trial
Bloomberg
Novartis
drug reps
physicians
physician payments
Flag link:
Drug companies are beginning to wake up to this new risk factor
Drug companies are beginning to wake up to this new risk factor
Marketwatch
pharma industry
co-pay coupons
Pfizer
Sanofi
Amgen
Novartis
Flag link:

Pages